Ultragenyx to Participate at Investor Conferences in September
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare genetic disease therapies, has announced its participation in three major investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare genetic disease therapies, has announced its participation in three major investor conferences in September 2025.
The company's leadership, including Chief Medical Officer Eric Crombez, M.D. and Chief Financial Officer Howard Horn, will participate in fireside chats and host one-on-one meetings at the Cantor Global Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 9), and Bank of America Global Healthcare Conference (September 23). All fireside chat sessions will be available via webcast on the company's investor relations website.
Details
News Market Reaction – RARE
On Sep 2, the first trading day after this news, RARE closed 6.91% above the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.
Cantor Global Healthcare Conference 2025 (New York, NY)
- Thursday, September 4, 2025, Eric Crombez, M.D., Chief Medical Officer and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY)
- Tuesday, September 9, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
Bank of America Global Healthcare Conference (London, UK)
- Tuesday, September 23, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.